STVN
Stevanato Group SpA
NYSE · Healthcare · Medical - Instruments & Supplies · IT
$12.70
−9.93%Nov 4, 2026, 13:38 UTC
Stevanato Group S.p.A. shares declined, prompting a shareholder investigation.
Source:Nov 3, 2026, 22:38 UTC
SueWallSt announced a pending investigation into whether Stevanato Group's disclosures to investors complied with U.S. securities laws.
Source:Nov 3, 2026, 14:00 UTC
Stevanato Group S.p.A. reported quarterly earnings of $0.18 per share, above the Zacks consensus estimate of $0.17 and compared with $0.16 per share a year earlier.
Source:Nov 3, 2026, 11:30 UTC
Stevanato Group S.p.A. announced third-quarter 2026 revenue of €326.1 million, up 8% year over year and 8% on an organic basis.
Source:Oct 20, 2026, 20:30 UTC
Stevanato Group announced that it will report its third-quarter 2026 financial results on November 3, 2026.
Source:Aug 9, 2026, 08:04 UTC
Stevanato Group divested its California-based subsidiary Balda C. Brewer, and updated its full-year outlook to reflect this divestiture.
Aug 4, 2026, 10:30 UTC
Stevanato Group reported an 8% increase in revenue to €302.0 million for the second quarter of 2026, with high-value solutions representing 45% of total revenue.
Jul 30, 2026, 10:30 UTC
Stevanato Group announced that liraglutide combination products using its Alina pen injector received marketing authorizations in multiple European countries.
Source:Jul 23, 2026, 06:04 UTC
Zhengchuan Co., Ltd. signed a long-term deep strategic cooperation agreement with SPAMI, a subsidiary of Stevanato Group, in pharmaceutical packaging intelligent manufacturing, standardized operation system construction, and global market expansion.
Source:Jun 8, 2026, 10:30 UTC
Stevanato Group introduced Deora, a pen injector platform for subcutaneous delivery in diabetes and weight management.
Source: